5 billion people have access to medicine 2 billion to go

Mission

The Access to Medicine Foundation stimulates and guides pharmaceutical companies to do more for the people living in low- and middle-income countries without access to medicine.

Who we are
What we analyse
How we drive change

NEW: latest framework for action by pharma companies on access to medicine

The methodology for the 2018 Access to Medicine Index has tighter focus on priority areas for action

The methodology for the 2018 Access to Medicine Index represents the latest good practice framework for pharmaceutical companies working to improve access to medicine. Developed through the Foundation’s consensus-building process, it pinpoints how and where pharmaceutical companies have the greatest potential to make medicine more accessible. It will track how 20 of the world’s largest research-based pharmaceutical companies address these priorities.

Read more >>

News and Events

The Lancet publishes commentary on AMR Benchmark

12 Oct 2017
A new Commentary published today in The Lancet discusses the potential of the new Antimicrobial Resistance Benchmark to stimulate pharmaceutical companies to limit antimicrobial resistance. The Commentary has been co-authored by Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, and Marc Mendelson, Professor of Infectious Diseases and Head of the Division of Infectious Diseases & HIV Medicine, Groote Schuur Hospital, University of Cape Town, South Africa.

New: latest framework for action by pharmaceutical companies on access to medicine

05 Oct 2017
Today, the Access to Medicine Foundation has published the methodology for the 2018 Access to Medicine Index. It pinpoints where pharmaceutical companies have the greatest potential for improving access to medicine in low- and middle-income countries.

Now online: first independent framework for assessing pharma company action on AMR

24 Aug 2017
Today, the Access to Medicine Foundation publishes the methodology for its 2018 Antimicrobial Resistance Benchmark. It is the first independently developed framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance (AMR).

New study finds wide variety in pharma companies’ cancer access programmes

18 May 2017
The Access to Medicine Foundation has systematically mapped how large research-based pharmaceutical companies are responding to the growing cancer crisis in low and lower-middle income countries.

The Access to Medicine Foundation has moved!

21 Apr 2017
The Access to Medicine Foundation has outgrown its former office in Haarlem and moved to a larger space in Amsterdam. The new office is close to the Amsterdam Sloterdijk station on Naritaweg 227-A, 1043 CB, Amsterdam.

Out now: the first Access to Vaccines Index

06 Mar 2017
The first Access to Vaccines Index will be published on Monday 6 March, 2017. It is the first tool of its kind to present the current landscape of vaccine company behaviour when it comes to making vaccines more accessible for the populations that need them.

Foundation to track pharma company progress on AMR

13 Dec 2016
The Access to Medicine Foundation has started work on a new tool – an Antimicrobial Resistance Benchmark that will track how pharmaceutical companies are responding to the increase in drug-resistance. The AMR Benchmark is currently funded by the UK and Dutch governments.
Access to Medicine Index Cover

Access to Medicine Index 2016

The only in-depth comparison of the world’s largest pharma companies on how they improve access to medicine for the poor.

Visit website

Access to Vaccines Index Cover

Access to Vaccines Index 2017

The first tool to show how vaccine companies are responding to calls to increase access to vaccines.

Visit website

We’re hiring!

New positions in Research, Strategy, AMR
Interested in working toward the next Access to Medicine Index or our new AMR Benchmark? Or in joining the Foundation’s Strategy team?

Investors

Access to medicine: a material issue for investors
Investors engage with the Foundation for insight into our analysis of the pharma sector, including into governance structures, R&D and pricing strategies.

The foundation on Twitter

Access to Medicine's Twitter avatar
Access to Medicine
@AtMIndex

Next Thursday, our @bethboyermph will speak on #access2meds, our current work on #AtMIndex2018, key findings & best… t.co/fbwbxwZKPc

Access to Medicine's Twitter avatar
Access to Medicine
@AtMIndex

Today, New Delhi: @damidefelice presenting the #AtMIndex2016 & its findings on #pharma co.s efforts to improve… t.co/sFPsIHDSoK

Access to Medicine's Twitter avatar
Access to Medicine
@AtMIndex

Tomorrow, our @damidefelice will join a panel on #infectiousdisease control at the 1st World Conference on Access t… t.co/on3MjUN8uz

Andreas Oszkiel's Twitter avatar
Andreas Oszkiel
@andreasoszkiel

@JayasreeKIyer Executive Director @AtMIndex speaking about our findings regarding opportunities to improve access a… t.co/rixGxmxpXo

Retweeted by Access to Medicine
Andreas Oszkiel's Twitter avatar
Andreas Oszkiel
@andreasoszkiel

@JayasreeKIyer Executive Director @AtMIndex speaking about access to medicine trends at @Novartis "Exploring the fu… t.co/LOrdIphedF

Retweeted by Access to Medicine
Encourage pharma companies Access to Medicine

Commentary

Incentivising pharma to develop medicine for the poor
Which mechanisms work for engaging pharma companies in R&D for diseases of poverty?

“To improve access, we believe pharmaceutical companies need to focus on how
they deploy their products, and, as global citizens, collaborate on the development of strong health systems.”

Jayasree K. Iyer, Executive Director, Access to Medicine Foundation.

1

Embedding pro-access governance

2

Mainstreaming inclusive business models

3

Improving industry responsiveness to public health priorities

4

Employing ‘access-thinking’ in product deployment

5

Addressing unmet needs through R&D

The Access to Medicine Foundation and its publications are funded by

Ukaid
Gates-foundation
Ministry-of-foreign-affairs-of-the-netherlands
Postcode-loterij